

# Effect of educative reminder telephone calls on human papillomavirus immunization rate

<b>Submission date</b> 08/06/2020	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 27/07/2020	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 10/10/2022	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Accounting for 569,847 new cases and 311,000 deaths in 2018, cervical cancer is classified as the fourth most frequent female cancer worldwide. Human papillomavirus, a sexually transmitted disease, is identified as the source of 99.7% of cervical cancers. Being the cause of essentially all cervical cancer, HPV is also related to vulva, vaginal, oropharyngeal, penis and anal cancers as well as genital warts. Available for more than a decade, HPV immunization is a very safe and effective primary prevention measure. The third and last available HPV vaccine launched in 2014 has been approved for females aged 9 to 45 and males aged 9 to 26. Unfortunately, despite being a largely preventable disease, wild variation in HPV coverage is observed among women depending on their race, incomes, geography and education level. To date, there is no research evaluating the use of educational phone calls to increase the HPV vaccination rate, particularly in a high-risk population. The aim of this study is to measure the effect of educative reminder telephone calls on HPV immunization rate.

### Who can participate?

Women who agree to get a prescription of HPV vaccination and understand French

### What does the study involve?

Participants will be randomly allocated to receive one (control group) or three (intervention group) phone calls to inform them about the HPV vaccination and also to answer their questions. The rate of HPV vaccination is measured after 6 months.

### What are the possible benefits and risks of participating?

The only drawbacks for patients are having one (control group) or a few (intervention group) phone follow-ups. No visit is planned. Participants will receive \$15 in compensation at the end of the study.

### Where is the study run from?

Sherbrooke University Hospital Center (Canada)

### Where is the study starting and how long is it expected to run for?

July 2019 to June 2020

Who is funding the study?

1. Sherbrooke University (Canada)
2. Merck Company Foundation (USA)

Who is the main contact?

Dr Jessica Ruel-Laliberté

jessica.ruel-laliberte@usherbrooke.ca

## Contact information

### Type(s)

Scientific

### Contact name

Dr Korine Lapointe-Milot

### Contact details

3001 12e Avenue N

Sherbrooke

Canada

J1H 5N4

+1 (0)819 346 1110

korine.lapointe-milot@usherbrooke.ca

### Type(s)

Public

### Contact name

Dr Jessica Ruel-Laliberte

### ORCID ID

<https://orcid.org/0000-0002-6108-838X>

### Contact details

3001 12e Avenue N

Sherbrooke

Canada

J1H 5N4

+1 (0)819 346 1110

jessica.ruel-laliberte@usherbrooke.ca

## Additional identifiers

### EudraCT/CTIS number

Nil known

### IRAS number

### ClinicalTrials.gov number

Nil known

## **Secondary identifying numbers**

2020-3319

# **Study information**

## **Scientific Title**

Effect of educative reminder telephone calls on human papillomavirus immunization rate: a randomised controlled trial

## **Study objectives**

Reminder educative phone calls increase the human papillomavirus (HPV) vaccination rate in adult women age 18 to 45 with risk factors of cervical cancer.

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Approved 25/09/2019, Sherbrooke Research Ethics Committee (3001, 12e avenue Nord, Sherbrooke, Canada; +1 (0)819 346-1110 #12856; [ethique.recherche.ciussse-chus@ssss.gouv.qc.ca](mailto:ethique.recherche.ciussse-chus@ssss.gouv.qc.ca)), ref: 2020-3319

## **Study design**

Interventional single-blind randomized controlled trial

## **Primary study design**

Interventional

## **Secondary study design**

Randomised controlled trial

## **Study setting(s)**

Hospital

## **Study type(s)**

Prevention

## **Participant information sheet**

Not available in web format, please use contact details to request a participant information sheet (available in French)

## **Health condition(s) or problem(s) studied**

Prevention of cervical cancer

## **Interventions**

The randomization schedule will be done in blocks of 6 in a 50:50 ratio. Allocation will only occur once the consent will be obtained. A secured order list made by a computer generator will determine the group allocation of each patient. Only the two principal authors will have access

to the secured computer list for the reminder educative telephone calls. Given the nature of the intervention, study investigators and research coordinators will not be blinded to treatment allocation.

All eligible participants will be given an initial recruitment questionnaire where risk factors of cervical cancer and immunization status are assessed. The risk factors identified are based upon a clinical gynecology oncology reference book (L. Stewart Massad, 2018). They will receive a file containing a three-dose HVP vaccine prescription, vaccination clinic contact list and an HPV virus information brochure from the Canadian Obstetric Gynaecology Society.

If a participant is assigned to the intervention group, she will receive a total of three standardised phone calls made by either the same author or one of the two research medical student involved at 1, 3 and 6 months after randomisation. During the first two interventions, callers will need to follow the instruction of an educative script and at each intervention call, participants will verbally inform research team if they got vaccinated and if not, investigators will ask what barriers they faced. If barriers identified concern lack of patient knowledge, the research team will provide a specific answer to any questions and calm any doubts or fear. If it concerns a logistical issue such as a loss of a prescription or not knowing where to get vaccinated, a new prescription will directly be made at the pharmacy and the vaccination clinic contact list will be provided by email or discussed by phone.

The control group will receive a phone call at 6 months to assess HPV immunization status and barriers to vaccination.

When patients do not answer phone calls, a total of two callbacks will be made and an email will be sent with the script and the two questions. Patients who will complete the study will receive a check by mail of 15 Canadian dollars each as a reward for their participation.

### **Intervention Type**

Behavioural

### **Primary outcome measure**

Rate of HPV vaccination at 6 months after randomisation

### **Secondary outcome measures**

1. Rates of vaccination measured using phone call at 6 months for high-risk patients in intervention and control groups. High-risk patients are categorized as presenting one or more of these risk factors: smoker or past smoker, more than two sexual partners in the past 12 months, low education status (high school or college), history of abnormal pap smear or had their last pap smear more than 3 years ago
2. Type and frequency of barriers to vaccination in intervention and control groups mentioned by non-vaccinated patients in a phone call at 6 months
3. Type and frequency of barriers to vaccination in intervention group mentioned in phone calls at 1 and 3 months which were overcome by recall calls

### **Overall study start date**

01/07/2019

### **Completion date**

01/06/2020

# Eligibility

## Key inclusion criteria

Women are eligible for study enrollment if:

1. They agree to get a prescription of HPV vaccination
2. Understand French

## Participant type(s)

Patient

## Age group

Adult

## Sex

Female

## Target number of participants

142

## Total final enrolment

130

## Key exclusion criteria

Women who:

1. Do not know their HPV immunization status
2. Refuse vaccination

## Date of first enrolment

01/10/2019

## Date of final enrolment

10/10/2019

# Locations

## Countries of recruitment

Canada

## Study participating centre

**Centre Hospitalier Universitaire de Sherbrooke**

3001, 12e Avenue Nord

Sherbrooke

Canada

J1H 5H3

# Sponsor information

**Organisation**

Centre Hospitalier Universitaire de Sherbrooke

**Sponsor details**

3001, 12e avenue Nord

Sherbrooke

Canada

J1H 5N3

+1 (0)819 346 1110

ethique.recherche.ciusse-chus@ssss.gouv.qc.ca

**Sponsor type**

Hospital/treatment centre

**Website**

<http://www.chus.qc.ca/en/>

**ROR**

<https://ror.org/020r51985>

**Funder(s)****Funder type**

Industry

**Funder Name**

Merck Company Foundation

**Alternative Name(s)****Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Trusts, charities, foundations (both public and private)

**Location**

United States of America

**Funder Name**

Université de Sherbrooke

**Alternative Name(s)**

University of Sherbrooke, UdeS, UDS

### **Funding Body Type**

Government organisation

### **Funding Body Subtype**

Universities (academic only)

### **Location**

Canada

## **Results and Publications**

### **Publication and dissemination plan**

Planned publication in a high-impact peer-reviewed journal.

### **Intention to publish date**

01/07/2020

### **Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Jessica Ruel-Laliberté ([jessica.ruel-laliberte@usherbrooke.ca](mailto:jessica.ruel-laliberte@usherbrooke.ca)).

### **IPD sharing plan summary**

Available on request

### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		01/01/2021	30/03/2021	Yes	No
<a href="#">Protocol file</a>	in French version 1	17/07/2019	10/10/2022	No	No